Chromatographic methods for simultaneous determination of diiodohydroxyquinoline and Metronidazole in their binary mixture

Two chromatographic methods were developed for analysis ofdiiodohydroxyquinoline [DIHQ] and metronidazole [MTN]. In the first method, diiodohydroxyquinoline and metronidazole were separated on TLC silica gel 60F254 plate using chloroform: acetone: glacial acetic acid [7.5: 2.5: 0.1, by volume] as mobile phase. The obtained bands were then scanned at 254 nm. The second method is a RP-HPLC method in which diiodohydroxyquinoline and metronidazole were separated on a reversed-phase C18 column using water: methanol [60 :40, V/V, PH=3.6] as mobile phase at a flow rate of 0.7 mL.min[-1] and UV detection at 220 nm. The mentioned methods were successfully used for determination of diiodohydroxyquinoline and metronidazole in pure form and in their pharmaceutical formulation

Spectrophotometric and spectrofluorimetric methods for determination of racecadotril

Two accurate and sensitive spectrophotometric and spectrofluorimetric methods were developed for determination of Racecadotril. In the first method reduction of Fe3+ into Fe2+ in presence of o-phenanthroline by Racecadotril to form a stable orange-red ferroin chelate [Fe- [Phen][3][2+] was the basis for its determination. The absorbance at 510 nm was measured and linear correlation was obtained in the concentration range of 2.5 - 25 microg mL[-1]. In the second method the native fluorescence of Racecadotril in acetonitril solvent at lambda, = 319 nm when excitation was at 252 nm is used for its determination. Linear correlation was obtained in the concentration range of 50 to 500 ng mL[-1]. The proposed methods were applied for determination of Racecadotril in bulk powder with mean accuracy of 100.39 +/- 1.239 for the spectrophotometric method and 100.09 +/- 1.042 for the spectrofluorimetric method. The proposed methods were successfully applied for determination of Racecadotril in its pharmaceutical dosage form

Transdermal nitroglycerin enhances lidocaine and neostigmine for intravenous anesthesia in patients undergoing hand surgery. a prospective randomized double blind placebo control study

In a prospective randomized blind study, we investigated the effects of adding transdermal nitroglycerine for lidocaine and neostigmine for intravenous regional anesthesia in adult patients undergoing hand surgery. Sixty patients [ASA grade I, aged 20-60 years] of both sexes were enrolled. The patients were randomly allocated to receive either 40ml of 0.5% lidocaine plus a transdermal placebo patch [control group n=15], 40ml of 0.5% lidocaine with 0.5mg of neostigmine plus a transdermal placebo patch [Neostigmine group, n=15], 40ml of 0.8% lidocaine plus a transdermal nitroglycerine patch [Nitroglycerine group, n=15] or 40ml of 0.5% lidocaine with O.smg of neostigmine plus a transdermal nitroglycerine patch [Neostigmine - Nitroglycerine group, n=15]. All routine hemodynamic parameters and O2 saturation were monitored, surgical time, sensory and motor block onset times, sensory and motor block recovery times and time to first analgesic requirement were measured. Operative conditions and quality of anesthesia were also recorded. Sensory and motor block onset times were shorter in the neostigmine - nitroglycerine group compared with all other groups [p<0.05]. Sensory block recovery time was significantly prolonged and the quality of anesthesia was better in the neostigmine - nitroglycerine group compared with all other groups [p<0.05]. We found that the addition of O.smg neostigmine to 40ml of 0.5% lidocaine for intravenous regional anesthesia with a 5mg transdermal nitroglycerine patch improved the operating conditions and quality of anesthesia and prolonged postoperative relief with no adverse effects